BioWorld

Nov. 30, 2007

Regeneron Signs Sanofi To Potential $1B Collaboration

Regeneron Pharmaceuticals Inc. and Sanofi-Aventis are collaborating to discover, develop and commercialize human therapeutic antibodies in a cash and stock deal potentially worth $1 billion. (BioWorld Today) Read More

Axcan Goes Private Through $1.3B TPG Acquisition Deal

For Cardioprotection, Akt Is Not Sole Actor, Study Finds

Medgenics' IPO Pulls £3.28M To Advance Biopump Efforts

MGI Reviews Strategic Options; Stays Mum On Prospective Deals

Other News To Note

Clinic Roundup

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...